News
3 Reasons Gilead Sciences Jumped to Buy Kite Pharma
Gilead Sciences Inc. (NASDAQ: GILD) might be the most disciplined capital allocator in biotech. For years, its management has resisted calls from the peanut gallery to make a big acquisition,....
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
On Monday, Gilead Sciences' (NASDAQ: GILD) wowed investors with an $11.9 billion deal to buy clinical-stage CAR-T drugmaker Kite Pharma (NASDAQ: KITE), and on Wednesday, the FDA approved Novartis'....
Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today
The major benchmarks posted gains on Wednesday, as geopolitical fears and hurricane concerns gave way to positive economic news. A report released by the U.S. Department of Commerce showed that....
10 Stocks That Have Doubled in the Last Year
Image Source: Getty Images.Long-term investors don't necessarily set out to find stocks that will double in a year, but it's certainly nice when that happens. Additionally, many stocks that have....
Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?
Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown with an agreement to acquire Kite Pharma Inc. (NASDAQ: KITE) for $180 per share or about $11.9 billion. Gilead's last....
3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma
Finally.Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Investors had long waited for the big biotech to make a deal. One....
3 Stocks to Buy With Dividends Yielding More Than 3%
Dividend stocks offer both income and long-term growth prospects. Smart dividend investors focus on the stocks that have the best chances of giving them both, maximizing their returns. Among
Why Luxoft Holding, Inc. Stock Plunged Today
Shares of Luxoft Holding Inc. (NYSE: LXFT) are plummeting today, down 28.2% as of 11:15 a.m. EDT, after the software engineering company posted disappointing fiscal first-quarter 2018 results
Luxoft Holding Inc. Compiles an Underwhelming Quarter
Luxoft Holding (NYSE: LXFT) announced weaker-than-expected fiscal first-quarter results on Thursday after the market closed, highlighting a seasonal slowdown and sluggish sales to the software
Why Shares of STMicroelectronics Popped Nearly 18% in July
Shares of STMicroelectronics (NYSE: STM) climbed 17.7% in July, according to data from S&P Global Market Intelligence, as investors grew more optimistic that the company would deliver strong
3 Energy Stocks to Buy at the Bottom of the Cycle
Energy stocks have been among the market's worst performers, and arguably, that's put many of the sector's leading stocks in the stock market's bargain bin. While crude oil prices might never get back
AGTA RECORD : First half-year sales 2017
Solid growth in order intake – Confirmation of 2017 goals
Growth of order intake reached 7.1 % compared to the same period last year which allows the group to confirm its 2017 goals for....
AGTA RECORD : Chiffre d'affaires du 1er semestre 2017
Progression des commandes et confirmation des objectifs 2017
La bonne progression des commandes au 1er semestre, +7,1% par rapport à l'an dernier, permet à agta record de confirmer ses....
3 Key Things Every CAR-T Investor Should Watch
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis
Here's Why Smart Sand Inc's Stock Is Sinking Today
Shares of frack sand producer Smart Sand (NASDAQ: SND) were falling on Thursday morning and were down more than 15% at 11 a.m. EDT following an analyst downgrade.That downgrade came from an analyst at
Why Transocean, Scripps Networks Interactive, and Exponent Jumped Today
The stock market gained ground on Wednesday, with the Nasdaq Composite pushing toward new records that date back to the end of the tech boom in early 2000. Earnings reports have started coming out at
Is It Too Late to Get In on This Millionaire-Maker Stock?
Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%.
Why You're Smart to Buy Vertex Pharmaceuticals Stock
You might look at Vertex Pharmaceuticals (NASDAQ: VRTX) stock and shake your head at its valuation. After soaring more than 70% so far in 2017, shares of the biotech now trade at a whopping 180 times
5 Things Transocean's Management Thinks You Should Know Heading Into Earnings Season
Few investors could have imagined that it would take more than three years for the offshore drilling market to pick back up when oil prices started to crash back in 2014. Yet here we are with
Is Juno Therapeutics Stock Still a Strong Buy?
Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from
Now's the Time to Buy These Stocks
Investors who started buying back into energy stocks last year may be starting to lose their patience. The oil price recovery that was supposed to start happening as underinvestment sinks its teeth
AGTA RECORD : Bilan semestriel du contrat de liquidité au 30 juin 2017
agta record
Société anonyme de droit suisse au capital de 13 334 200 CHF
Siège social : Allmendstrasse 24, CH, 8320 Fehraltorf
Registre du commerce de Zurich CH 020 3900 8220
Exercice....
TELEVERBIER : Résultats du 1er semestre 2016/2017
Le Conseil d'Administration du 19 juin 2017 a examiné les comptes consolidés (non audités) du 1er semestre 2016/2017.
Compte de résultat consolidé (01.11.2016 au 30.04.2017)
Pour mémoire, le....
Die Zehnder Group tritt auf der Stelle!
Liebe Leser,
Zehnder kommt nicht von der Stelle. Die hohe Gewinnsteigerung mit einem Jahresgewinn von 20,3 Mio € täuscht über die tatsächliche operative Lage hinweg. Das Gewinnplus ging auf einen....
Ypsomed: Auf Erfolgskurs!
Liebe Leser,
Ypsomed bleibt auf Erfolgskurs. Der Umsatz wurde im 1. Halbjahr um 17,5% gesteigert. Das operative Ergebnis kletterte um 45% auf 28,1 Mio SFr. Skaleneffekte (höhere....